Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals, Inc. - Common Stock
(NQ:
APLS
)
25.17
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
19
20
Next >
12 Health Care Stocks Moving In Monday's Intraday Session
↗
July 17, 2023
Via
Benzinga
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
July 17, 2023
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...
Via
Benzinga
Ford Motor, AT&T, Frontier Communications And Other Big Stocks Moving Lower On Monday
↗
July 17, 2023
U.S. stocks traded higher, with the Dow Jones gaining over 50 points on Monday. Here are some big stocks recording losses in today’s session. Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares...
Via
Benzinga
The Latest Analyst Ratings for Apellis Pharmaceuticals
↗
June 13, 2023
Via
Benzinga
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is a Stock Spotlight on 5/25
May 25, 2023
Via
Investor Brand Network
Apellis Pharma Crashes After Safety Report Undercuts Its Newest Eye Drug
↗
July 17, 2023
Now, investors are questioning the future for Apellis' Syfovre, an eye-disease treatment.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
July 17, 2023
Via
Benzinga
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
↗
July 17, 2023
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
July 17, 2023
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!
Via
InvestorPlace
Needham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
↗
May 05, 2023
Via
Benzinga
Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views
↗
May 05, 2023
The company easily beat sales calls on the back of Syfovre, a geography atrophy drug.
Via
Investor's Business Daily
The Latest Analyst Ratings for Apellis Pharmaceuticals
↗
May 05, 2023
Via
Benzinga
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 10, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals: Q1 Earnings Insights
↗
May 04, 2023
Via
Benzinga
Earnings Preview: Apellis Pharmaceuticals
↗
May 03, 2023
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
↗
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
↗
May 25, 2023
Via
Benzinga
Why Shares of Annexon Are Plummeting Thursday
↗
May 25, 2023
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.
Via
The Motley Fool
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
May 25, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Why These 3 Nasdaq Stocks Buckled Today
↗
May 16, 2023
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.
Via
The Motley Fool
Are Small Caps a Harbinger of Market Declines?
May 09, 2023
The iShares Russell 2000 ETF outperformed the S&P 500 last week, but that may be short-lived. Small-cap momentum is often a bellwether for broad-market action.
Via
MarketBeat
Topics
ETFs
Stocks
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations
↗
May 05, 2023
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported Q1 revenues of $44.8 million, surpassing the consensus of $26.10 million and
Via
Benzinga
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
May 04, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
↗
May 01, 2023
These three biotech stocks were on the volatile side today.
Via
The Motley Fool
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
↗
May 01, 2023
The company is working on a treatment for the eye disease known as geographic atrophy.
Via
Investor's Business Daily
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
